Login to Your Account



Beware the 'Simple' Path: Combo Drug/Devices Tricky

By Marie Powers
Staff Writer

Thursday, April 11, 2013
Pity the poor drug developer that thinks using the combination drug/device regulatory pathway through the FDA's Office of Combination Products could be a shortcut to approval, bypassing the sometimes unpredictable regulatory oversight of the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription